LL37 (5mg)
$90.00
Description
A single-component research material supplied for controlled research environments. LL-37 is a synthetic cathelicidin-derived peptide used in research exploring innate immunity, antimicrobial pathways, and wound-healing models in controlled systems.
Composition
• LL-37
• Appearance: Lyophilized powder in a sealed research vial
Research Focus (non-clinical)
• Characterization of LL-37 in antimicrobial activity assays
• Studies on immune modulation and inflammatory pathway signaling
• Evaluation in cell culture and tissue models related to epithelial repair
• Stability and solubility profiling under laboratory storage conditions
For qualified research professionals and institutional laboratories. Not for human use.
Documentation & Quality Assurance
Each lot is sourced through our verified global supply chain with emphasis on traceability and quality control. We work diligently to obtain and maintain third-party analytical reports (HPLC/LC-MS) and Certificates of Analysis for each batch, as part of our ongoing quality process. These documents are reviewed internally and displayed as they become available. Independent third-party testing is also performed on select lots to confirm identity, purity, and alignment with our internal specifications.
Important Notice
This product is intended for laboratory research use only. It is not intended for human or veterinary use, and must not be used for diagnostic, therapeutic, or clinical purposes.
This material is not a drug, medical device, or dietary supplement, and has not been evaluated by the U.S. Food and Drug Administration.
Quality & Manufacturing
All materials are sourced from carefully vetted domestic and international manufacturing partners who follow quality systems consistent with ISO and cGMP principles. Each supplier is reviewed for reliability, documentation integrity, and transparency in testing.
We require a verified purity of 99% or higher and perform independent third-party spot testing to confirm that select lots meet our internal standards for identity, purity, and composition. Where available, endotoxin testing results are included on Certificates of Analysis to verify laboratory purity; their inclusion is for research quality assessment only and does not imply suitability for human or veterinary use.
All research materials are sealed for integrity and packaged for stability during storage and transport from manufacturing through final delivery.
Additional information
| Weight | 0.05 lbs |
|---|
Storage Instructions
Certificate of Analysis

Research Use Only
These studies reference research-grade peptides for laboratory and scientific investigation only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Published Scientific Research
Peer-reviewed laboratory research investigating research peptides from leading scientific databases
A sonosensitive diphenylalanine-based broad-spectrum antimicrobial peptide.
The antimicrobial effect of antimicrobial peptides is typically slow; they can be rapidly biodegraded and often have non-selective toxicity and elaborate sequences. Here we report a short peptide that is activated by ultrasound, that shows high broad-spectrum antibacterial efficiency (>99%) against clinically isolated methicillin-resistant bacteria (specifically, Staphylococcus aureus, Escherichia coli, Staphylococcus epidermidis, Enterobacter cancerogenus and Pseudomonas aeruginosa) with 15 m
View Full StudyResearch progress in the role of ultraviolet in the pathogenesis of rosacea.
Its pathophysiological mechanisms involve multiple factors.
View Full StudyCathelicidin LL-37 in periodontitis: current research advances and future prospects - A review.
LL-37 is the sole member of the cathelicidin family of antimicrobial peptides in humans, primarily produced by phagocytic leukocytes and epithelial cells, mediating a wide range of biological responses. Discovered in human neutrophils, LL-37 is known for its broad-spectrum antimicrobial activity and immunomodulatory functions. In periodontitis, LL-37 is mainly expressed in gingival epithelium, gingival sulcus fluid, and saliva. Emerging evidence from several studies suggests that LL-37 is signif
View Full StudyAntimicrobial peptide CRAMP/LL-37 mediates ferroptosis resistance in cardiomyocytes by inhibiting cathepsin L.
However, its specific role and mechanism in ferroptosis are unclear. Finally, the regulatory mechanism of CRAMP in ferroptosis was verified in vivo by mouse myocardial infarction model.
View Full StudyThe nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis.
These data, obtained using LL37 as a model autoantigen, indicate that citrullination and carbamylation pathways may play a role in the psoriasis course, generating epitopes to which immunological tolerance does not exist and potentially concur to PsA development.
View Full StudyMilk-derived extracellular vesicles functionalized with anti-tumour necrosis factor-α nanobody and anti-microbial peptide alleviate ulcerative colitis in mice.
In mice with chronic UC, simultaneously introducing VHH and an antimicrobial peptide LL37 into EV (EV), then administering orally improved intestinal barrier, inflammation and microbiota balance, resulted in relief of UC-induced depression and anxiety. Collectively, we demonstrated that oral delivery of EV effectively alleviated UC in mice and TAT efficiently loaded biologics into EV to confer protection from degradation in the gastrointestinal tract.
View Full Study



